PNC-27 (30 mg Vial) Dosage Protocol

Quickstart Highlights

PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes^[1]^[2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data^[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.

Typical daily range: 100–500 mcg once daily (gradual titration).

Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = 10 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	100 mcg (0.10 mg)	1 unit (0.01 mL)
Weeks 3–4	200 mcg (0.20 mg)	2 units (0.02 mL)
Weeks 5–8	300 mcg (0.30 mg)	3 units (0.03 mL)
Weeks 9–12	400 mcg (0.40 mg)	4 units (0.04 mL)
Weeks 13–16	500 mcg (0.50 mg)	5 units (0.05 mL)

Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Critical Note: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established^[3]. Any dosing above a few hundred micrograms per day is purely speculative^[4].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (PNC-27, 30 mg each):

8 weeks ≈ 1 vial (~15–20 mg total used)
12 weeks ≈ 1 vial (~25 mg total used)
16 weeks ≈ 2 vials (~35–40 mg total used)

Insulin Syringes (U‑100 or 30/50‑unit for precision):

Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
12 weeks (1 vial): 3 mL → 1 × 10 mL bottle
16 weeks (2 vials): 6 mL → 1 × 10 mL bottle

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100‑count boxes
12 weeks: 168 swabs → recommend 2 × 100‑count boxes
16 weeks: 224 swabs → recommend 3 × 100‑count boxes

View Supplier

Protocol Overview

Concise summary of the once‑daily regimen.

Goal: Educational exploration of a p53‑derived peptide studied preclinically for selective cancer‑cell membrane disruption^[1]^[2].

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).

Dose Range: 100–500 mcg daily with gradual titration.

Reconstitution: 3.0 mL per 30 mg vial (10 mg/mL) for simplified unit measurements.

Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.